Indication

Non-squamous non-small cell lung cancer (NSCLC) with high c-Met protein overexpression

Non-squamous non-small cell lung cancer (NSCLC) with high c-Met protein overexpression is a biomarker-defined subtype of epithelial lung malignancy that predominantly encompasses adenocarcinomas and large cell carcinomas. Read more about Non-squamous non-small cell lung cancer (NSCLC) with high c-Met protein overexpression

1 drugs 1 manufacturers

Advertisement

Drugs that treat it

Common Non-squamous non-small cell lung cancer (NSCLC) with high c-Met protein overexpression therapies.

Showing 1–1 of 1 drugs

Filter & compare in the drug finder →Opens the drug finder with Non-squamous non-small cell lung cancer (NSCLC) with high c-Met protein overexpression preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Non-squamous non-small cell lung cancer (NSCLC) with high c-Met protein overexpression.

Non-squamous non-small cell lung cancer (NSCLC) with high c-Met protein overexpression is a biomarker-defined subtype of epithelial lung malignancy that predominantly encompasses adenocarcinomas and large cell carcinomas.

Pathophysiologically, the condition is defined by abundant cell-surface density of the c-Met receptor tyrosine kinase—commonly established by immunohistochemistry demonstrating strong membrane staining in a substantial majority of malignant cells—driven by transcriptional upregulation, autocrine signaling, or genomic alterations.

This elevated receptor expression promotes sustained oncogenic signaling through downstream proliferative and anti-apoptotic cascades, often conferring aggressive tumor behavior, therapeutic resistance, and a poorer overall clinical prognosis.

Personalize your experience

Follow Non-squamous non-small cell lung cancer (NSCLC) with high c-Met protein overexpression and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it